170 related articles for article (PubMed ID: 16325050)
1. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity.
Bruck H; Leineweber K; Temme T; Weber M; Heusch G; Philipp T; Brodde OE
J Am Coll Cardiol; 2005 Dec; 46(11):2111-5. PubMed ID: 16325050
[TBL] [Abstract][Full Text] [Related]
2. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.
Liu J; Liu ZQ; Tan ZR; Chen XP; Wang LS; Zhou G; Zhou HH
Clin Pharmacol Ther; 2003 Oct; 74(4):372-9. PubMed ID: 14534524
[TBL] [Abstract][Full Text] [Related]
3. The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart.
Huntgeburth M; La Rosée K; ten Freyhaus H; Böhm M; Schnabel P; Hellmich M; Rosenkranz S
Clin Res Cardiol; 2011 Aug; 100(8):641-7. PubMed ID: 21311897
[TBL] [Abstract][Full Text] [Related]
4. The beta-adrenoceptor subtype(s) mediating adrenaline- and dobutamine-induced blood pressure and heart rate changes in healthy volunteers.
Daul A; Hermes U; Schäfers RF; Wenzel R; von Birgelen C; Brodde OE
Int J Clin Pharmacol Ther; 1995 Mar; 33(3):140-8. PubMed ID: 7599912
[TBL] [Abstract][Full Text] [Related]
5. [Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure].
Yu WP; Lou M; Deng B; Song HM; Wang HB
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Sep; 34(9):776-80. PubMed ID: 17217681
[TBL] [Abstract][Full Text] [Related]
6. The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines.
La Rosée K; Huntgeburth M; Rosenkranz S; Böhm M; Schnabel P
Pharmacogenetics; 2004 Nov; 14(11):711-6. PubMed ID: 15564877
[TBL] [Abstract][Full Text] [Related]
7. Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine.
Yogev D; Basheer M; Blotnick S; Caraco Y; Muszkat M
Pharmacogenet Genomics; 2015 Nov; 25(11):555-63. PubMed ID: 26313487
[TBL] [Abstract][Full Text] [Related]
8. Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers.
Schwartz SG; Puckett BJ; Allen RC; Castillo IG; Leffler CT
Ophthalmology; 2005 Dec; 112(12):2131-6. PubMed ID: 16325708
[TBL] [Abstract][Full Text] [Related]
9. The Arg389Gly beta1-adrenoceptor polymorphism does not affect cardiac effects of exercise after parasympathetic inhibition by atropine.
Leineweber K; Bruck H; Temme T; Heusch G; Philipp T; Brodde OE
Pharmacogenet Genomics; 2006 Jan; 16(1):9-13. PubMed ID: 16344717
[TBL] [Abstract][Full Text] [Related]
10. Effect of the Arg389Gly β₁-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment.
Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Hjelvang BR; Henriksen T; Frandsen E; Forman JL; Torp-Pedersen C; Køber L; Poulsen HE
Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):779-85. PubMed ID: 22703382
[TBL] [Abstract][Full Text] [Related]
11. In patients chronically treated with metoprolol, the demand of inotropic catecholamine support after coronary artery bypass grafting is determined by the Arg389Gly-beta 1-adrenoceptor polymorphism.
Leineweber K; Bogedain P; Wolf C; Wagner S; Weber M; Jakob HG; Heusch G; Philipp T; Brodde OE
Naunyn Schmiedebergs Arch Pharmacol; 2007 Jul; 375(5):303-9. PubMed ID: 17541557
[TBL] [Abstract][Full Text] [Related]
12. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
13. Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.
Joseph SS; Lynham JA; Grace AA; Colledge WH; Kaumann AJ
Br J Pharmacol; 2004 May; 142(1):51-6. PubMed ID: 15037517
[TBL] [Abstract][Full Text] [Related]
14. Cardiac reserve in the transplanted heart: effect of a graft polymorphism in the beta1-adrenoceptor.
Scharin Täng M; Lindberg E; Grüner Sveälv B; Magnusson Y; Andersson B
J Heart Lung Transplant; 2007 Sep; 26(9):915-20. PubMed ID: 17845930
[TBL] [Abstract][Full Text] [Related]
15. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure.
Mialet Perez J; Rathz DA; Petrashevskaya NN; Hahn HS; Wagoner LE; Schwartz A; Dorn GW; Liggett SB
Nat Med; 2003 Oct; 9(10):1300-5. PubMed ID: 14502278
[TBL] [Abstract][Full Text] [Related]
16. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects.
O'Shaughnessy KM; Fu B; Dickerson C; Thurston D; Brown MJ
Clin Sci (Lond); 2000 Sep; 99(3):233-8. PubMed ID: 11787477
[TBL] [Abstract][Full Text] [Related]
17. Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors.
McLean RC; Baird SW; Becker LC; Townsend SN; Gerstenblith G; Kass DA; Tomaselli GF; Schulman SP
Am J Cardiol; 2012 Oct; 110(7):1001-7. PubMed ID: 22742717
[TBL] [Abstract][Full Text] [Related]
18. The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β(1) adrenergic receptor antagonist esmolol in healthy individuals.
Muszkat M; Hoofien A; Orlanski-Meyer E; Makhoul H; Porat E; Davidson EM; Blotnick S; Caraco Y
Pharmacogenet Genomics; 2013 Jan; 23(1):25-8. PubMed ID: 23114278
[TBL] [Abstract][Full Text] [Related]
19. Job strain, job demands and adrenergic beta1-receptor-polymorphism: a possible interaction affecting blood pressure in men.
Ohlin B; Berglund G; Nilsson PM; Melander O
J Hypertens; 2008 Aug; 26(8):1583-9. PubMed ID: 18622236
[TBL] [Abstract][Full Text] [Related]
20. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
